WHO ICTRP trial
Efficacy and safety of Cadonilimab(AK104) plus SOX as a neoadjuvant regimen in…
ChiCTR2300072695 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2300072695 |
|---|---|
| Public title | Efficacy and safety of Cadonilimab(AK104) plus SOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm open-label phase II trial |
| Scientific title | Efficacy and safety of Cadonilimab( AK104) plus SOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm open-label phase II trial |
| Primary sponsor | Department of Oncology, The First People's Hospital Affiliated to Yangtze University, |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | gastric cancer |
| Interventions | Test group:Cadonilimab 10mg/kg iv drip,d1 q3w; 3 cycles Oxaliplatine 130mg/m2 iv drip,d1 q3w 3cycles S-1 40-60mg bid d1-d14 q3W 3cycles |
| Registration date | Jun 21, 2023 |
| Target size | Test group:10 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: